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Objective: To undertake a comparative evaluation of diagnostic modalities used in the detection of hepatitis C virus 
(HCV) infection by serum antibody in ELISA and HCV-RNA in the serum as well as in the liver tissue of the same patients 
with chronic liver disease by reverse transcription-polymerase chain reaction (RT-PCR). 
Methods: Thirty-five subjects comprising 30 cases of cirrhosis of the liver and five cases of chronic hepatitis were 
included in the study group. The criteria for including the subjects in the study were the availability and quality of serum 
and liver samples. Serologic ELISA tests for HCV antibody as well as HBsAg and anti-HBc IgG for hepatitis B virus (HBV) 
were performed on the patient's sera, while RT-PCR was carried out with RNA extracted from both serum and liver 
biopsies of the patients. Primer sequences selected from the conserved NS5 region of the HCV genome were used in 
Results: Of 30 cases of cirrhosis studied, five (16.6%) were anti-HCV antibody positive, while seven (23.3%) were 
positive for HCV RNA in serum and 10 (33.3%) were positive in liver tissue. One of the anti-HCV antibody-positive patients 
was negative for HCV RNA in both liver and serum by PCR. All seven patients who showed positivity for HCV RNA in 
serum were also positive for HCV RNA in the liver. Another three cirrhosis cases (10%) found to be HCV positive in liver 
tissue were negative for both antibody and HCV RNA in serum. Of the five cases of chronic hepatitis, two (40%) were 
found to be positive by all three tests. HCV was found to be more prevalent in HBV-infected cases (8/18; 44.5%). However, 
two of the three cirrhotic patients who showed HCV positivity only in liver PCR tested negative for HBV surface antigen. 
Conclusions: RT-PCR detection of HCV RNA in liver tissue is of significant clinical importance and is more reliable 
than RT-PCR in serum or antibody tests by ELISA. RT-PCR can effectively complement antibody tests for reliable 
diagnosis, since assessment of HCV positivity by a single test seems to be inadequate. The frequent association of HCV 
infection with HBV suggests that hepatitis B and C viruses may share similar modes of transmission in India. 
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RT-PCR. 
INTRODUCTION 
Hepatitis C virus (HCV), a positive-stranded RNA 
virus, which is considered to be a major etiologic agent 
of parented non-A, non-B (NANB) hepatitis, has been 
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recently cloned and characterized [l]. Most patients 
who acquire HCV infection later develop chronic 
infection and liver diseases [ 2 ] .  A high proportion of 
individuals acutely infected with HCV become chroni- 
cally infected, and more than 20% of these individuals 
will eventually develop liver cirrhosis [3] with an in- 
creased risk of developing hepatocellular carcinoma 
(HCC) [4,5]. HCV infection is also known to be 
associated with some autoimmune diseases [6,7]. Thus, 
significant morbidity and mortality are caused by HCV 
infection worldwide. 
The recent development of various serologic 
diagnostic tests for the detection of antibodies to HCV, 
based on recombinant viral proteins derived fi-om the 
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nucleic acid sequences of the HCV genome, has made 
possible the detection of HCV infection 181. Other 
sensitive methods of diagnosing HCV infection include 
the detection of viral nucleic acids in serum by the 
reverse transcription-polymerase chain reaction (KT- 
PCK). By the use of KT-PCR, the majority of anti- 
HCV antibody-positive patients can be shown to be 
carriers of the HCV RNA genome, which can also be 
detected in some anti-HCV-negative patients [9]. 
Although the RT-PCR detection of HCV genome 
circulating in serum is certainly an important and useful 
technique, it does not help in understanding how it 
affects the liver, which is presumed to be the reservoir 
and primary site of viral replication. The contribution 
of HCV to cryptogenic cirrhosis, autoimmune chronic 
or active hepatitis, etc., suggested by serum studies 
[ 10, I 11, requires the positive identification of HCV 
genome in the liver. Because of intermittent viremia, 
HCV KNA may be undetectable in serum but it should 
be present in liver tissue [12,13]. Several authors have 
shown that HCV RNA can be detected in the liver 
in both freshly frozen and formalin-fixed paraffin- 
embedded tissues 114-161. 
Although there have been reports of detection of 
HCV KNA in serum, as well as in liver tissue, in 
European and American populations 115-171, no 
equivalent study has yet been carried out in an Indian 
population. Therefore, the present study has been 
undertaken to detect HCV KNA and also anti-HCV 
antibody in both the serum and liver tissue of patients 
with chronic liver diseases to understand the extent of 
viral infection and their role in liver disorders in India, 
where viral hepatitis is a major public-health problem. 
MATERIALS AND METHODS 
Patients and materials 
The study group included a total of 35 cases comprising 
30 patients with cirrhosis of the liver and five cases of 
chronic hepatitis who were admitted during the period 
between April 1995 and March 1996 to the medical 
wards of LNJP hospital, New Delhi. The diagnosis of 
liver cirrhosis was made when the patient presented 
with the features of chronic liver disease associated with 
portal hypertension, biochemical evidence of hepato- 
cellular failure and liver biopsy showing the histologic 
features of cirrhosis. Similarly, the diagnosis of chronic 
hepatitis was made when the patient presented with a 
history of acute viral hepatitis, and showed symptomatic, 
biochemical or serologic evidence of continuing inflam- 
matory liver disease for more than 6 months, and liver 
histology showed the features of chronic hepatitis. 
The criteria for including subjects in the study 
were the availability and quality of serum and liver 
samples. The routine investigations carried out included 
hemogram (full blood count including Hb, total 
leukocyte count (TLC), differential leukocyte count 
(DLC), etc.), kidney function tests and various liver 
function tests such as serum glutamate oxalacetate 
transaminase (SGOT), serum glutamate pyruvate 
transaminase (SGPT), alkaline phosphatase, pro- 
thrombin time, serum bilirubin and serum proteins 
with albumin to globulin ratio. Liver biopsy was done 
in all cases to establish the histologic diagnosis after 
informed consent was given by the patients. The serum 
samples collected from the patients were stored at 
-70°C until use. Liver biopsy was performed with a 
sterile disposable liver biopsy needle and the material 
stored in a -70°C freezer until RNA extraction. 
Serologic tests 
The presence of antibodies to HCV (anti-HCV) was 
tested using a third-generation ELISA kit (Inno-Test 
HCV A6 I11 kit, Innogenetics Nv., Ghent, Belgium), 
which detects antibodies against core and non-structural 
proteins NS3, NS4 and NS5. The anti-HCV antibody- 
positive samples were confirmed by a third-generation 
recombinant immunoblot assay (KIBA-3, Chiron 
Corporation, Emeryville, CA, USA). HBV positivity 
was determined by an ELISA for HBsAg (Micro Elisa 
strips; Kanbaxy Diagnostics, London, UK) and anti- 
HBc IgG (anti-HBc lut; Melotest, Barcelona, Spain). 
RNA extraction from serum and liver tissue 
RNA was extracted from serum and liver tissue by 
the acid guanidinium thiocyanate-phenol-chloroform 
method [18] with minor modifications [19]. Briefly, 
100 pL of serum, or approximately 10 mg of liver 
biopsy, was homogenized in a small volume (200- 
300 pL) of lysis buffer containing 4 M guanidinium 
thiocyanate (GTC), 0.75 M sodium citrate (PH 7.0), 
5% N-lauryl sarcosyl and 0.1 M P-mercaptoethanol, 
using glass pestles and matched tubes separately for each 
sample, and incubated in 500 pL (final volume) of lysis 
buffer for 30 min on ice. To this, 60 pL of sodium 
acetate (3 M, pH 4.0) was added and kept for another 
10 min. The homogenate was extracted once with 
500 pL ofwater-saturated phenol and 100 pL of chloro- 
form, and once with 600 pL of chloroformhoamyl 
alcohol (24: l), precipitated with absolute ethanol and 
air dried. Finally, the pellet was dissolved in 20 pL of 
sterile DEPC (diethyl pyrocarbonate) water and stored 
at -70°C until use. 
Synthesis of cDNA and polymerase chain reaction (RT-PCR) 
Reverse transcription for the synthesis of cDNA and 
nested PCR was performed in a single reaction tube 
using 5 pL of RNA extracted from either serum or liver 
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tissue. Briefly, 50 pL of the reaction mixture containing 
25 mM MgC12,25 mM dNTPs, 50 ng of bovine serum 
albumin (BSA), 5 pL ofx1O PCR buffer, 20 pmol each 
of outer primers HC-1 and HC-2, 0.5 pL (20 U/pL) 
of avian megaloblastosis virus (AMV) reverse transcrip- 
tase (Promega, Madison, WI, USA) and 0.5 U of Eq 
DNA polymerase (Promega) was incubated at 42°C for 
1 h. The first round of PCR was carried out in a Cetus 
DNA thermal cycler (Perkin Elmer Cetus, Roche, NJ, 
USA) for 35 cycles following reverse transcription with 
denaturation for 4 min only for the first cycle and later 
for 1 min at 94”C, annealing for 90 s at 50°C and exten- 
sion for 2 min at 72°C. Positive and negative controls 
were included in every PCR amplification experiment. 
AU necessary precautions for the extraction of RNA 
and carrying out RT-PCR were strictly followed in 
order to avoid cross-contamination and carryover PCR. 
The following primer sequences were selected 
&om the conserved NS5 region of the HCV genome 
with a final amplimer size of 251 bp. The oligonucleo- 
tide primers were synthesized in a DNA synthesizer 
(Model 381 A; Applied Biosystems Inc., Foster City, 
CA, USA) by the phosphoroamidate method and 
purified in an NAP 10 column (Pharmacia, Uppsala, 
Sweden) according to the manufacturer’s protocol. 
Outer primers 
HC-1(+): 
HC-2(-): 
5 ’ 4 T G  TGA GGA ACT ACT GTC TT-3’. 
5’-GTG CTC ATG GTG CAC GGT CTA CGA 
GAC CTC CCG-3’. 
Inner primers 
HC-3(+): 
HC-4(-): 
5’-TTC ACG CAG AAA GCG TCT AG-3’. 
5’-CAC TCG CAA GCA CCC TAT CAG GCA 
TGC A-3’. 
The reaction mix and temperature profile for the 
second round of PCR were the same as in the first 
PCR, except that its outer primers were replaced by 
the inner nested primers HC-3 and HC-4. A one- 
tenth volume (5 pL) of the first PCR product was 
added as template to 40 1 L  of the second PCR mix, 
and amplification was carried out again for 35 cycles. 
Finally, 15-20 pL of the amplified PCR products was 
analyzed by electrophoresis in a 3% agarose (FMC 
Bioproducts, Rockland, ME, USA) gel containing 0.5 
p g / d  ethidium bromide. The expected amplified 
PCR product of 251 bp was identified and photo- 
graphed under a UV transilluminator (Figure 1). The 
doubtful cases, such as those antibody-negative but 
PCR-positive cases, were reconfirmed by RT-PCR 
with a separate set of primers provided in the Inno- 
LiPA HCV I1 kit (Innogenetics NV, Zwijnaarde, 
Belgium). A selected number of cases were also 
screened for the presence of HBV DNA using a pair of 
*= 
:gl 2 3 4 5 6 7 8 9 1 0  
I-- 
- Q  
bP 
1353 
1078 & 
872 - 
251 bp - (HCV) 
234 
194 
118J/ 
72 
Figure 1 Detection of HCV RNA sequences in liver 
tissue and serum of patients with chronic liver diseases by 
reverse transcription-nested PCR. Ethidium bromide- 
strained 3% Nusieve agarose gel showing an expected 
amplified product of 251 bp indicative of HCV positivity. 
Lanes 3, 5 ,  7 and 9 are liver tissue RNA samples, and lanes 
4, 6, 8 and 10 are RNA samples &om serum; lanes 1 and 2 
are negative and positive controls, respectively. 
primers derived from the core region of the HBV 
genome (nucleotide position 2269-241 5 bp; upstream 
5‘-GGA GTG TGG ATT CGC ACT-3’ and down- 
stream 5’-TGA GAT CTT CTG CGA CGC-3’). The 
size of the PCR product was 147 bp. 
RESULTS 
The 35 cases of chronic liver disease, comprising 30 cases 
of cirrhosis and five cases of chronic hepatitis, were 
evaluated for the presence ofHCV by PCR and serology. 
In the cirrhosis group there were 19 (63.3%) males and 
11 (36.7%) females, whde in the chronic hepatitis group 
all the five cases were males. The mean ages for the 
chronic hepatitis and the cirrhosis patients were 32k6.1 
years and 40.53k10.8 years respectively. Table 1 shows 
that a total of 10 (33.4%) of the 30 cases of cirrhosis and 
two (40%) of the five cases of chronic hepatitis were 
found to have evidence of HCV infection, either in 
serum or a biopsy, as revealed by amplification of an 
expected amplimer of 251 bp in an RT-PCR assay 
(Figure 1). Anti-HCV antibody was found in only five 
(16.7%) of the 30 cases of cirrhosis and in two (40%) of 
five chronic hepatitis cases. HCV RNA could be 
detected in serum in seven (23.3%) of the 30 cases of 
cirrhosis and in two (40%) of the five cases of chronic 
hepatitis, whde in the liver tissue viral R N A  was detected 
in 10 (33.4%) of the cirrhosis patients and in two (40%) 
of the chronic hepatitis patients. 
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Table 1 Comparative analysis of H C V  positivity by using anti-HCV antibody (ELISA) and RT-PCR methods in serum 
and in liver tissue in patients with cirrhosis of the liver and chronic hepatitis 
~~ 
Diagnostic methods employed 
Cirrhosis of liver 
(n=30) 
Chronic hepatitis 
(n=5) 
ELISA positive (anti-HCV) 5 (16.7%) 2 (40) 
Serum RNA KT-PCR positive 7 (23.3%) 2 (40%) 
Liver KNA RT-PCR positive i n  (33.3%) 2 (40) 
ELISA positive, PCR negative 1 (3.33%)” 0 
Liver PCR posinve, serum PCR negative 3 (10%) 0 
Serum PCR positive, liver PCR negative 0 0 
Total HCV positivity 10 (33.4%) 2 (40%) 
”Not considered as positive. 
Table 2 Positivity test of HBV by various diagnostic viral 
markers in patients with cirrhosis and chronic hepatitis 
_ _ _ _ ~  
Type of viral Cirrhocis of h e r  Chronic hepatitis 
marker used (n=30) (n=5) 
HBsAg 9 (30%) 3 (60%) 
Anti-HBc 15 (50%) 2 (40%) 
anti-HBc negative 3 (30%) 1(20%) 
anti-HBc positive 9 (30%) 0 
HBsAg positive, 
HBsAg negative. 
Total HBV infection 18 (60%) 3 (60%) 
Interestingly, one patient in the cirrhosis group was 
positive for anti-HCV antibody but negative for HCV 
RNA in both serum and liver tissue, and hence she has 
not been included in the total HCV positivity count. 
All the seven patients who were positive for HCV 
RNA in the serum were also found to be positive in 
liver tissue. However, there were three cases (10%) in 
which HCV could be detected only in liver tissue and 
they were negative for both anti-HCV antibody and 
HCV RNA in serum. The HCV positivity was recon- 
firmed by using another set of primers used in the LiPA 
Innogenetics assay (Innogenetics, Ghent, Belgium). 
The amplified first (300 bp) or second (240 bp) PCR 
product was compared with the LiPA gel control for 
confirmation. 
The status of serologic markers for hepatitis B virus 
(HBV) in these patients was also evaluated. As shown 
in Table 2, nine (30%) of the 30 cirrhosis patients were 
HBsAg positive, 15 (50%) were anti-HBc positive and 
three (10%) were HBsAg positive but anti-HBc 
negative, while nine (30%) cases were HBsAg negative 
but anti-HBc positive. Thus, HBV infection in terms 
of HBsAg and/or anti-HBc positivity was found in 18 
(60%) cases of cirrhosis. Of the five patients with 
chronic hepatitis, three (60%) were HBsAg positive and 
two (40%) were anti-HBc positive. HCV infection was 
found in eight (44.4%) of the 18 HEN-positive and two 
(16.6%) of the 12 HBV-negative cases of cirrhosis. Two 
HCV-positive chronic hepatitis cases were also found 
to harbor HBV infection. Of the three cirrhotic patients 
who were HCV positive only in liver PCR, two were 
negative and only one was positive for HBV surface 
antigen (HBsAg) (Table 3). 
Table 3 Status of H C V  and HBV serologic markers of the 10 HCV-positive cirrhosis patients 
HCV status HBV status 
Serial HCV RNA HCV RNA 
No. Patient’s code Sex/Age Anti-HCV serum liver HBsAg Anti-HBC HBeAg 
_ _ _ _ _ _ _ _ _ _ ~  
1 J/LNH F40 Positive Positive Positive Negative Positive Positive 
3 BB/LNH F38 Negative Negative Positive” Positive Negative Negative 
4 RC/LNH F40 Negative Positive Positive Negative Positive Positive 
5 NJ/LNH F40 Positive Positive Positive Negative Negative Negative 
6 RD/LNH F44 Negative Negative Positivea Negative Negative Negative 
7 DMS/LNH M45 Negative Positive Positive Positive Negative Negative 
8 S/LNH M24 Positive Positive Positive Positive Positive Positive 
9 HA/LNH M42 Negative Negative Positive’ Negative Negative Positive 
10 MS/LNH M46 Positive Positive Positive Negative Positive Negative 
”HCV positive only by liver PCR. 
7 
I BB/LNH M35 Negative Positive Positive Negative Positive Positive 
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DISCUSSION 
The present study highlights the importance of RT- 
PCR detection of HCV RNA in both serum and liver 
tissues along with HCV antibody status in the same 
patients with chronic liver disease. Although several 
investigators have used different quantitative techniques 
to determine the viral load in the serum samples of 
HCV-infected patients with different liver hsorders, 
the results are contradictory. In the present study, HCV 
RNA could be detected in the serum of seven patients 
who were also positive in liver tissue. Observation of 
HCV RNA only in the liver tissue and its absence in 
the serum suggests that the HCV genome can be 
detected in the liver in the presence or in the absence 
of viremia. This is consistent with the earlier findings 
by Savage et a1 [13], but it is in sharp contrast to the 
recent report of DeMoliner et al [20] that HCV RNA 
in serum is a mirror of viral replication in the liver. The 
absence of HCV RNA in the serum but its presence in 
the liver tissue may be due to intermittent viremia or a 
very low level of viremia. 
We also observed that hepatitis B virus (HBV) 
infection is more common among HCV-positive cases 
than HCV-negative ones (Table 2) .  This finding implies 
that HBV and HCV may share similar modes of 
infection, as has been suggested by other authors 
[21-23].The failure to detect anti-HBc positivity in 
three patients who were HBsAg positive may be due to 
mutation in the core region, since all of them were 
found to be positive for HBV DNA in a PCR test. 
The present study shows that anti-HCV antibody 
could be detected in 16.7% of the cases of chronic liver 
disease and is consistent with the findings of other 
workers [24-261. One patient of the cirrhosis group 
was anti-HCV antibody positive, but negative for HCV 
RNA in serum and liver tissue. This may be due to 
either fluctuation of HCV RNA levels or an emer- 
gence of an HCV mutant. It could be due to residual 
past infection also. It is interesting that five cirrhosis 
patients, two of whom were positive for serum as well 
as liver HCV RNA and three for only liver PCR, were 
negative for antibodies by the third-generation ELISA 
test. This suggests that the host immune response was 
weakened or that these HCV strains had genetic 
heterogenicity [27]. It may be a false-negative result 
because of differences between the infecting genotype 
of HCV and the genotypic origin of the antigens used 
in this third-generation ELISA test which is based on 
type 1 antigens. Dhaliwal et al [28] demonstrated that 
reactivity of samples with type 2 or type 3 genotypes is 
reduced 4-5-fold compared with type 1 samples in this 
test. This seems to be true, since our recent study 
(Gangwal et al, unpublished), and also reports of other 
authors, indicate that types 2b and 3 are found to be 
most prevalent in this northern region of India [29] 
while in southern India genotype l b  was the pre- 
dominant type [30]. Thus, it is quite possible that a 
certain proportion of such HCV infections may not be 
picked up by the current antibody assays, since the 
present third-generation ELISA is based on type 1 
antigens located in the NS4 region (aa 1683-1764), 
which does not show subtype-specific serologic reac- 
tivities. Indeed, genotyping of isolates from the above 
five cirrhosis patients who were anti-HCV negative but 
HCV PCR positive either in serum or in liver revealed 
three of type 2b and two of type 3a (data not 
presented). Therefore, multiple NS4 peptides based on 
the sequence of the most prevalent subtypes need to be 
employed to achieve adequate sensitivities for type 2 or 
type 3 serotypes. 
Significant differences in reactivity to type 1 NS4 
antigens by antibodies to subtypes 2a and 2b have also 
been reported by Yuki et al [23]. Therefore, though 
the majority of people rely mainly on various antibody 
tests, they are clearly not completely reliable, and 
RT-PCR should be used to complement the antibody 
tests to improve diagnosis, meaningful interpretation, 
and treatment. 
It is suggested that the detection of HCV RNA in 
serum by RT-PCR has better diagnostic value than the 
anti-HCV antibody tests alone and that HCV RNA 
detection in liver tissue is possible even when it is absent 
in the serum. Our observation that HCV may persist 
in the liver in the absence of PCR positivity in serum 
gains strong support from the recent report of Haydon 
et al [31], who showed that patients may clear virus 
from serum to become serum PCR. negative but 
remain antibody positive in serum and liver PCR 
positive. It is also known that antibody titer may decline 
to an undetectable level in serum PCR-negative 
individuals. Therefore, it appears that initially a patient 
may be HCV positive by all tests but clears virus from 
the serum later and becomes serum PCR negative, yet 
remains antibody positive and liver PCR positive [31]. 
Finally, the patient may lose antibody &om serum to 
become antibody negative and serum PCR negative, 
yet remain liver PCR positive (present report). How- 
ever, such patients who are antibody negative and 
serum PCR negative are generally not considered to be 
at risk for developing long-term liver disease like 
cirrhosis, even if the virus is detected by PCR in liver. 
Interestingly, there are three such cirrhosis cases in the 
present study, which suggests that HCV PCR positivity 
in liver may have clinical significance. However, one 
may argue that the real clinical significance may not lie 
with liver HCV positivity, but may be the presence of 
HBV infection in these patients. This seems to be not 
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the complete answer, since of the three cirrhotic patients 
who were positive only in liver PCR,  two of them were 
negative and only one was positive for HBV surface 
antigen (Table 3 ) .  Furthermore, out of the total of 10 
HCV-infected cirrhotic patients, only three were 
positive for HBsAg, five showed anti-HBc positivity, 
and two showed complete absence of HEW (Table 3 ) .  
The present findings are clinically important and not 
unusual, since HCV replicates mainly in the liver, 
which usually contains a larger number of viral copies 
than are found in the serum. It is therefore suggested 
that along with an anti-HCV test, RT-PCR assay for 
liver R N A  needs to be carried out to reach a meaning- 
ful conclusion. In individuals who are repeatedly 
negative for anti-HCV or HCV R N A  in the serum by 
RT-PCR but show clinical signs suggestive of liver 
disease, a liver biopsy should be examined for HCV 
R N A  by RT-PCR to rule out active chronic HCV 
infection. Nevertheless, the presence of several geno- 
types of HCV or its mutants, which often show 
geographic variations, demands great care in choosing 
the primers and interpreting RT-PCR test results. 
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